Olverembatinib (HQP1351)
POLARIS-3
Ascentage Pharma · Phase 3 · Recruiting · Enrollment 40
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|
No efficacy figure is in this file for this study.
GIST
Programs, trials, and reported response and survival for gastrointestinal stromal tumor.
Olverembatinib (HQP1351)
Ascentage Pharma · Phase 3 · Recruiting · Enrollment 40
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|
No efficacy figure is in this file for this study.